Serina Therapeutics Announces Material Definitive Agreement
Ticker: SER · Form: 8-K · Filed: Apr 14, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Apr 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, corporate-action
TL;DR
Serina Therapeutics signed a big deal, sold some stock, and changed its rules. Big moves ahead.
AI Summary
Serina Therapeutics, Inc. announced on April 8, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and material modifications to the rights of security holders. The filing also includes amendments to its articles of incorporation or bylaws and a Regulation FD disclosure.
Why It Matters
This filing indicates significant corporate actions, including potential new financing or strategic partnerships, which could impact the company's future operations and stock value.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- April 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38519 (company_file_number) — SEC File Number
- 82-1436829 (ein) — IRS Employer Identification No.
- 601 Genome Way, Suite 2001, Huntsville, Alabama 35806 (address) — Principal executive offices
- AgeX Therapeutics, Inc. (company) — Former company name
- 20170606 (date) — Date of former company name change
FAQ
What is the nature of the material definitive agreement Serina Therapeutics entered into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on April 8, 2025.
What were the terms of the unregistered sales of equity securities?
The filing indicates unregistered sales of equity securities occurred but does not provide specific details on the terms, amounts, or prices.
What specific modifications were made to the rights of security holders?
The filing states there were material modifications to the rights of security holders, but the specific details of these modifications are not provided in the summary information.
What are the key items covered in the Regulation FD Disclosure?
The filing mentions a Regulation FD Disclosure, but the specific content of this disclosure is not detailed in the provided summary.
When did Serina Therapeutics change its name from AgeX Therapeutics, Inc.?
Serina Therapeutics, Inc. changed its name from AgeX Therapeutics, Inc. on June 6, 2017.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 regarding Serina Therapeutics, Inc. (SER).